OSE Immunotherapeutics Presents New Gene Expression Signature at AACR 2025

OSE Immunotherapeutics, in collaboration with the Léon Bérard Cancer Center, presented a promising development in cancer treatment at the 2025 AACR Annual Meeting. The research team unveiled a new composite gene expression signature (cGES) that improves the prediction of clinical responses in patients undergoing immune checkpoint blockade (ICB) therapy. This innovation aims to enhance personalized treatment irrespective of cancer type.

Current biomarkers for ICB, such as PD-L1 expression, have notable limitations. The newly developed cGES seeks to address these gaps, offering a more consistent prediction of patient responses. It stratifies cancer patients into three groups with distinct clinical outcomes, potentially guiding therapeutic decisions across multiple cancer types. This advancement could play a pivotal role in improving patient survival and treatment efficacy.

Professor Pierre Saintigny emphasized the potential of this cGES to significantly refine personalized cancer care. The breakthrough, spearheaded by OSE Immunotherapeutics and Léon Bérard's collaborative efforts, signifies a step forward in cancer treatment personalization.